TY - JOUR
T1 - Prediction of medication noncompliance in outpatients with schizophrenia
T2 - 2-year follow-up study
AU - Yamada, Kazuo
AU - Watanabe, Koichiro
AU - Nemoto, Naoyuki
AU - Fujita, Hidechika
AU - Chikaraishi, Chikayo
AU - Yamauchi, Keita
AU - Yagi, Gohei
AU - Asai, Masahiro
AU - Kanba, Shigenobu
N1 - Funding Information:
This work was supported by funding from Ohme Keiyu Hospital, Ohme, Tokyo, Japan (Doctor N. Otsuka, Director).
PY - 2006/1/30
Y1 - 2006/1/30
N2 - Neuroleptic noncompliance is a major reason for relapse in outpatients with schizophrenia. In a 2-year follow-up study, we used the Japanese version of the Rating of Medication Influences Scale (ROMI-J) to investigate the reasons for compliance and noncompliance in outpatients with schizophrenia. Ninety outpatients who were confirmed by interview to have had good compliance for more than 3 months completed the initial interview, which included the Clinical Global Impressions Scale (CGI), the Brief Psychiatric Rating Scale (BPRS), the Global Assessment of Functioning Scale (GAF), the UKU Side Effect Rating Scale, and the ROMI-J. All the outpatients were followed up for 2 years. At the initial interview, the most frequent reason for compliance was "relapse prevention," while the most frequent reason for noncompliance was "distressed by side effects." Fifteen outpatients who proved to be noncompliant in the follow-up period had higher baseline BPRS "agitation" scores and ROMI-J "no perceived daily benefit" ratings than compliant patients. Sixty-four outpatients who maintained compliance during the follow-up had higher baseline ROMI-J ratings of "fulfillment of life goals" than their noncompliant counterparts. It is important to understand the attitudes of patients with schizophrenia toward drug therapy in order to predict better compliance and provide psychoeducation designed to forestall relapses.
AB - Neuroleptic noncompliance is a major reason for relapse in outpatients with schizophrenia. In a 2-year follow-up study, we used the Japanese version of the Rating of Medication Influences Scale (ROMI-J) to investigate the reasons for compliance and noncompliance in outpatients with schizophrenia. Ninety outpatients who were confirmed by interview to have had good compliance for more than 3 months completed the initial interview, which included the Clinical Global Impressions Scale (CGI), the Brief Psychiatric Rating Scale (BPRS), the Global Assessment of Functioning Scale (GAF), the UKU Side Effect Rating Scale, and the ROMI-J. All the outpatients were followed up for 2 years. At the initial interview, the most frequent reason for compliance was "relapse prevention," while the most frequent reason for noncompliance was "distressed by side effects." Fifteen outpatients who proved to be noncompliant in the follow-up period had higher baseline BPRS "agitation" scores and ROMI-J "no perceived daily benefit" ratings than compliant patients. Sixty-four outpatients who maintained compliance during the follow-up had higher baseline ROMI-J ratings of "fulfillment of life goals" than their noncompliant counterparts. It is important to understand the attitudes of patients with schizophrenia toward drug therapy in order to predict better compliance and provide psychoeducation designed to forestall relapses.
UR - http://www.scopus.com/inward/record.url?scp=29444457381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29444457381&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2004.07.014
DO - 10.1016/j.psychres.2004.07.014
M3 - Article
C2 - 16318875
AN - SCOPUS:29444457381
SN - 0165-1781
VL - 141
SP - 61
EP - 69
JO - Psychiatry research
JF - Psychiatry research
IS - 1
ER -
